GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Brainsway BWAY · USD

Health Care · US listing · 🇺🇸 United States

Compare

11.64

+4.39%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Brainsway

Its shares trade under the ticker BWAY. It has been listed since 6 October 1999. In the fiscal year to 31 December 2025, it reported revenue of $52.2m and net income of $7.6m. At that date it held total assets of $112.9m and shareholders' equity of $73.2m.

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious and late-life depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Health Care Equipment & Supplies
Listed since
6 Oct 1999
Employees
129
Head office
16 HARTUM STREET RAD TOWER, 14TH FLOOR, Jerusalem, L3, 9777516
Incorporated in
L3
Classification
Surgical & Medical Instruments & Apparatus
Filer status
Accelerated filer

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Deep Transcranial Magnetic Stimulation platform treats major depressive disorders in the US market.
  • 129 employees support global operations across Health Care sector.
  • Founded in 2003, BrainsWay serves psychiatry medical centers internationally.

Weaknesses

  • Limited to US and international markets without specific country expansion details.
  • No mention of product pricing or cost structure in the facts.
  • Headquarters in Jerusalem may limit local market access in some regions.

Opportunities

  • Expanding treatment applications for Alzheimer's disease in aging populations.
  • Growing demand for noninvasive mental health treatments in the US.
  • Potential for partnerships with hospitals in Europe for psychiatric care.

Threats

  • Competition from other Health Care companies in mental health sector.
  • Regulatory changes affecting neurostimulation device approvals.
  • Economic downturns reducing healthcare spending in the US market.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.